Obesity Hypoventilation Syndrome (BMI ≥30, Severe OSA): When First-Line CPAP Has Not Corrected Daytime Hypercapnia

This protocol addresses patients with obesity (BMI ≥30 kg/m²), daytime hypercapnia (PaCO₂ ≥45 mmHg), and sleep-disordered breathing with concomitant severe obstructive sleep apnoea (AHI ≥30 events/h) in whom first-line CPAP therapy has not achieved adequate arterial blood gas control.

Clinical Scenario

Obesity hypoventilation syndrome (OHS) is defined by obesity (BMI ≥30 kg/m²), daytime hypercapnia, and sleep-disordered breathing. Approximately 70% of OHS patients have concomitant severe OSA (AHI ≥30 events/h), making CPAP the standard first-line treatment modality for this subgroup.

Previous Treatment — Goal Not Achieved

First-line continuous positive airway pressure (CPAP) with PAP titration during sleep — as part of a multimodality approach including weight reduction and increased physical activity — did not achieve correction of daytime hypercapnia (PaCO₂ <45 mmHg) despite objectively documented high adherence, assessed over the first 2–3 months of therapy.

Next-Line Approach (Partial Summary)

Patients who fail to respond to CPAP despite good adherence are switched to noninvasive ventilation (NIV).

Titration parameters, monitoring schedule, and the complete management steps are available in the full structured protocol below.

Treatment Goals

Reduction in daytime arterial carbon dioxide tension (PaCO₂) and an increase in arterial oxygen tension (PaO₂), reassessed at approximately 2 months from initiation.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1183/16000617.0097-2018

Obesity hypoventilation syndrome (OHS) is defined as a combination of obesity (body mass index ⩾30 kg·m⁻²), daytime hypercapnia (arterial carbon dioxide tension ⩾45 mmHg) and sleep disordered breathing, after ruling out other disorders that may cause alveolar hypoventilation.
Nearly 70% of patients have concomitant severe OSA (AHI ⩾30 events·h⁻¹).
CPAP is considered the first-line treatment modality for OHS phenotype with concomitant severe obstructive sleep apnoea, whereas NIV is preferred in the minority of OHS patients with hypoventilation during sleep with no or milder forms of obstructive sleep apnoea (approximately <30% of OHS patients).
If patients initially treated with CPAP have no favourable response to therapy despite objectively documented high levels of adherence to CPAP, they should be changed to NIV therapy.
NIV consists of the application of positive-pressure ventilation, usually with bi-level pressure settings.
Ventilatory support produces an improvement in gas exchange, which translates into a significant reduction in daytime wake PaCO₂ and an increase in arterial oxygen tension.

View source ↗